UCB SA (UCB.VI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jean-Christophe Tellier | CEO & Executive Director | 4.07M | -- | 1959 |
| Ms. Sandrine Dufour CFA | Executive VP, CFO & Chief Corporate Development | -- | -- | 1966 |
| Ms. Denelle J. Waynick Johnson J.D. | Executive VP & General Counsel | -- | -- | 1967 |
| Mr. Jean-Luc Fleurial | Executive VP & Chief Human Resources Officer | -- | -- | 1965 |
| Mr. Emmanuel Caeymaex | Executive VP & Chief Commercial Officer | -- | -- | 1969 |
| Dr. Kirsten Lund-Jurgensen Ph.D. | Executive Vice President of Patient Supply | -- | -- | 1960 |
| Ms. Fiona du Monceau | Executive Vice President of Patient Evidence | 32.84k | -- | 1978 |
| Ms. Caroline Vancoillie | Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions | -- | -- | -- |
| Mr. Alistair Henry | Executive VP & Chief Scientific Officer | -- | -- | 1967 |
| Ms. Antje Witte | Head of Investor Relations | -- | -- | -- |
UCB SA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 9,052
Description
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Corporate Governance
Upcoming Events
April 25, 2025 at 12:00 AM UTC
Ex-Dividend Date
July 23, 2025 at 5:00 AM UTC - July 28, 2025 at 5:00 AM UTC
UCB SA Earnings Date
Recent Events
August 23, 1970 at 12:00 AM UTC
Dividend Date